The remarkably high cure rates being reported with the newest hepatitis C drugs are only likely to be used by a tiny percentage of people who need them.
23 hours ago | HIV i-Base
We, the undersigned, are organizations of people living with hepatitis C virus (HCV), HIV, and our allies. We believe in equitable access to life-saving treatment for all who need it. We write to express our indignation over Gilead’s pricing and licensing policies for the HCV drug, sofosbuvir.
23 hours ago | Petitionbuzz
Combined fixed-dose tablet of darunavir and cobicistat can help reduce number of pills in a combination antiretroviral treatment regimen.
23 hours ago | Janssen press release
Evotaz is coformulated to be one pill, once-daily, combining the protease inhibitor atazanavir, which is marketed as Reyataz (atazanavir 200 mg/300 mg) capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences, Inc.
23 hours ago | Bristol-Myers Squibb press release
The European AIDS Treatment Group and AVAC organized an unprecedented three-day workshop: New Developments in HIV Prevention. See http://eatgavacprevention.tumblr.com for more. In addition to comprehensive updates on product pipelines across the prevention research landscape, the group discussed the anticipation of the first data from European oral PrEP trials and the implications for PrEP access in Europe.
28 January 2015 | AVAC
GS-5816 is an important anti-hepatitis C compound that, in combination with sofosbuvir, will greatly simplify treatment for developing countries. However, it appears that none of the terms and conditions of the original licence agreement has been changed, meaning that the concerns that MSF has with the licence agreement remain, including the limited geographic scope of the agreement, restrictions on the production and export of active pharmaceutical ingredient, and the inclusion of an ethically and medically controversial and problematic anti-diversion clause.
27 January 2015 | Médecins Sans Frontières press release
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C. The expanded agreements will allow Gilead’s India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together account for 54 percent of the total worldwide population of individuals infected with the hepatitis C virus (HCV).
27 January 2015 | Gilead press release
On 22 January 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dutrebis, 150 mg lamivudine/300 mg raltegravir, film-coated tablet intended for the treatment of human immunodeficiency virus (HIV 1) infection in adults, adolescents, and children.
26 January 2015 | Street Insider
New intellectual property ‘think tank’ draft policy already showing alarming trend.
23 January 2015 | Medecins Sans Frontieres press release
Julio Cesar Cruz is an HIV patient and organizer with the Peruvian Network of Patients and Consumers . He participated in the demonstration and explained that, “The people who live with HIV in the country, are complaining that the Peruvian state is ...
21 January 2015 | TeleSUR